https://assets.capyfin.com/instruments/678fdc13234e27009c5d5c88.png avatar
uniQure
🇳🇱 NASDAQ:QURE
View Company
OverviewEarningsDividends
•
Dec 31, 2022

uniQure Q4 2022 Earnings Report

uniQure reported financial results for 2022 and highlighted recent progress across its business.

Key Takeaways

uniQure had a strong ending to 2022 with the approval of the world’s first gene therapy for hemophilia B. The company is working to advance AMT-130 and preparing for the initiation of two new Phase I/II studies in refractory temporal lobe epilepsy and SOD1-ALS.

Achieved U.S. and European Commission marketing approvals of first and only gene therapy for adults with hemophilia B

Advancing development of AMT-130 for patients with Huntington’s disease – clinical update from U.S. Phase I/II trial expected in second quarter 2023

Hosted virtual investor event featuring AMT-260 in refractory temporal lobe epilepsy - expected to enter clinical development in second half of 2023

Expanded pipeline with in-licensing of AMT-162 for SOD1 ALS - plans to initiate a Phase I/II clinical trial in the second half of 2023

Total Revenue
$103M
Previous year: $57.7M
+78.1%
EPS
$0.15
Previous year: $0.17
-11.8%
Gross Profit
$101M
Previous year: $55.9M
+81.6%
Cash and Equivalents
$393M
Previous year: $556M
-29.4%
Free Cash Flow
-$59.7M
Previous year: -$50.6M
+18.0%
Total Assets
$705M
Previous year: $809M
-12.9%

uniQure

uniQure

Forward Guidance

uniQure provided forward-looking statements regarding their clinical trials and regulatory submissions.

Positive Outlook

  • AMT-130 clinical trial for Huntington’s Disease will begin enrollment in the U.S. in the second half of 2023
  • The Company will announce one to two-years of follow up data from the U.S. Phase I/II clinical study of AMT-130 in the second quarter of 2023
  • Clinical data from the lower-dose cohort for AMT-130 is expected to be presented in the second half of 2023
  • The Company will submit an investigational new drug application for Fabry disease in 2023
  • The company will initiate a Phase I/II clinical study of AMT-162 for the treatment of ALS in the second half of 2023

Challenges Ahead

  • Risks associated with the regulatory approval and commercial launch of HEMGENIX®
  • Risks associated with our clinical trial for Huntington’s disease
  • Impact of financial and geopolitical events on our Company and the wider economy and health care system
  • Risks associated with our Commercialization and License Agreement with CSL Behring
  • Risks associated with our clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims

Company Overview

Full financial data and analysis

View uniQure